Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

A Mutation in Histone H2B Represents a New Class of Oncogenic Driver.

Bennett RL, Bele A, Small EC, Will CM, Nabet B, Oyer JA, Huang X, Ghosh RP, Grzybowski AT, Yu T, Zhang Q, Riva A, Lele TP, Schatz GC, Kelleher NL, Ruthenburg AJ, Liphardt J, Licht JD.

Cancer Discov. 2019 Jul 23. doi: 10.1158/2159-8290.CD-19-0393. [Epub ahead of print]

PMID:
31337617
2.

An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia.

Swaroop A, Oyer JA, Will CM, Huang X, Yu W, Troche C, Bulic M, Durham BH, Wen QJ, Crispino JD, MacKerell AD Jr, Bennett RL, Kelleher NL, Licht JD.

Oncogene. 2019 Jan;38(5):671-686. doi: 10.1038/s41388-018-0474-y. Epub 2018 Aug 31.

3.

Emerging Approaches for the Identification of Protein Targets of Small Molecules - A Practitioners' Perspective.

Comess KM, McLoughlin SM, Oyer JA, Richardson PL, Stöckmann H, Vasudevan A, Warder SE.

J Med Chem. 2018 Oct 11;61(19):8504-8535. doi: 10.1021/acs.jmedchem.7b01921. Epub 2018 Jun 6.

PMID:
29718665
4.

Polycomb- and REST-associated histone deacetylases are independent pathways toward a mature neuronal phenotype.

McGann JC, Oyer JA, Garg S, Yao H, Liu J, Feng X, Liao L, Yates JR 3rd, Mandel G.

Elife. 2014 Sep 24;3:e04235. doi: 10.7554/eLife.04235.

5.

C-terminal domain small phosphatase 1 and MAP kinase reciprocally control REST stability and neuronal differentiation.

Nesti E, Corson GM, McCleskey M, Oyer JA, Mandel G.

Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):E3929-36. doi: 10.1073/pnas.1414770111. Epub 2014 Sep 2.

6.

Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies.

Oyer JA, Huang X, Zheng Y, Shim J, Ezponda T, Carpenter Z, Allegretta M, Okot-Kotber CI, Patel JP, Melnick A, Levine RL, Ferrando A, Mackerell AD Jr, Kelleher NL, Licht JD, Popovic R.

Leukemia. 2014 Jan;28(1):198-201. doi: 10.1038/leu.2013.204. Epub 2013 Jul 4. No abstract available.

7.

Cardiovascular and systemic microvascular effects of anti-vascular endothelial growth factor therapy for cancer.

Belcik JT, Qi Y, Kaufmann BA, Xie A, Bullens S, Morgan TK, Bagby SP, Kolumam G, Kowalski J, Oyer JA, Bunting S, Lindner JR.

J Am Coll Cardiol. 2012 Aug 14;60(7):618-25. doi: 10.1016/j.jacc.2012.02.053. Epub 2012 Jun 13.

8.

Aberrantly silenced promoters retain a persistent memory of the silenced state after long-term reactivation.

Oyer JA, Yates PA, Godsey S, Turker MS.

Mutat Res. 2011 Jan 10;706(1-2):21-7. doi: 10.1016/j.mrfmmm.2010.10.006. Epub 2010 Oct 28.

9.

Aberrant epigenetic silencing is triggered by a transient reduction in gene expression.

Oyer JA, Chu A, Brar S, Turker MS.

PLoS One. 2009;4(3):e4832. doi: 10.1371/journal.pone.0004832. Epub 2009 Mar 12.

Supplemental Content

Support Center